Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol by Setiabudi, Wega et al.
1Setiabudi W, et al. BMJ Open 2021;11:e048317. doi:10.1136/bmjopen-2020-048317
Open access 
Prospective observational study of 
SARS- CoV-2 infection, transmission 
and immunity in a cohort of households 
in Liverpool City Region, UK (COVID- 
LIV): a study protocol
Wega Setiabudi   ,1 Daniel Hungerford   ,1,2,3 Krishanthi Subramaniam,1 
Natasha Marcella Vaselli,1 Victoria E Shaw,4 Moon Wilton,5 Roberto Vivancos,2,3,6 
Stephen Aston   ,1 Gareth Platt,1 Tracy Moitt,7 Ashley P Jones,7 Mark Gabbay,2,8 
Iain Buchan   ,3,9 Enitan D Carrol,1 Miren Iturriza- Gomara,1,3 Tom Solomon,1,2,10 
William Greenhalf,4 Dean J Naisbitt,11 Emily R Adams,2,12 Nigel A Cunliffe,1,3 
Lance Turtle,1,2 Neil French,1,2 on behalf of the COVID- LIV Study Group
To cite: Setiabudi W, 
Hungerford D, Subramaniam K, 
et al.  Prospective observational 
study of SARS- CoV-2 
infection, transmission and 
immunity in a cohort of 
households in Liverpool City 
Region, UK (COVID- LIV): a 
study protocol. BMJ Open 
2021;11:e048317. doi:10.1136/
bmjopen-2020-048317
 ► Prepublication history and 
supplemental material for this 
paper is available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
048317).
WS and DH contributed equally.
WS and DH are joint first 
authors.
Received 22 December 2020
Revised 17 February 2021
Accepted 01 March 2021
For numbered affiliations see 
end of article.
Correspondence to
Professor Neil French;  
 french@ liverpool. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction The emergence and rapid spread of 
COVID-19 have caused widespread and catastrophic 
public health and economic impact, requiring governments 
to restrict societal activity to reduce the spread of the 
disease. The role of household transmission in the 
population spread of SARS- CoV-2, and of host immunity 
in limiting transmission, is poorly understood. This paper 
describes a protocol for a prospective observational study 
of a cohort of households in Liverpool City Region, UK, 
which addresses the transmission of SARS- CoV-2 between 
household members and how immunological response to 
the infection changes over time.
Methods and analysis Households in the Liverpool City 
Region, in which members have not previously tested 
positive for SARS- CoV-2 with a nucleic acid amplification 
test, are followed up for an initial period of 12 weeks. 
Participants are asked to provide weekly self- throat 
and nasal swabs and record their activity and presence 
of symptoms. Incidence of infection and household 
secondary attack rates of COVID-19 are measured. 
Transmission of SARS- CoV-2 will be investigated against 
a range of demographic and behavioural variables. Blood 
and faecal samples are collected at several time points to 
evaluate immune responses to SARS- CoV-2 infection and 
prevalence and risk factors for faecal shedding of SARS- 
CoV-2, respectively.
Ethics and dissemination The study has received 
approval from the National Health Service Research 
Ethics Committee; REC Reference: 20/HRA/2297, IRAS 
Number: 283 464. Results will be disseminated through 
scientific conferences and peer- reviewed open access 
publications. A report of the findings will also be shared 
with participants. The study will quantify the scale and 
determinants of household transmission of SARS- CoV-2. 
Additionally, immunological responses before and during 
the different stages of infection will be analysed, adding to 
the understanding of the range of immunological response 
by infection severity.
INTRODUCTION
Within months of the first reports of a novel 
respiratory disease in Wuhan, China, in 
December 2019, COVID-19 has been declared 
a global pandemic with devastating impacts.1 
The disease caused by the SARS- CoV-2 has 
reached 46.8 million cases and 1.2 million 
deaths globally as of 3 November 2020, 
although the real number is likely to be much 
higher.2 With limited evidence of effective 
prophylactic treatment and prior to wide-
spread availability of vaccination, countries 
Strengths and limitations of this study
 ► Liverpool Household COVID-19 Cohort Study is a 
prospective cohort study of households that aims to 
represent the socioeconomic profile of the Liverpool 
City Region population, which enables the determi-
nation of risk factors of SARS- CoV-2 transmission 
while minimising recall bias.
 ► This household- based study will identify pau-
cisymptomatic and asymptomatic COVID-19 cases, 
thus allowing the measurement of their contribution 
to transmission.
 ► The longitudinal nature of the study enables the 
capture of subjects before they test positive for 
COVID-19, which provides a preinfection and post-
infection time point to evaluate changes to the host 
immune response.
 ► Limitations include the relatively small sample size 
and repeated self- sampling, which may lead to di-
agnostic inconsistencies.
 ► Participation bias by those most engaged with 
COVID-19 and disease control may theoretically re-
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around the world have been forced to implement various 
forms of restriction to individual movement in order to 
control the transmission of SARS- CoV-2.3–5 Although the 
effectiveness of such measures in controlling viral trans-
mission comes at the cost of disruption in socioeconomic 
activity and mental well- being, the impact from uncon-
trolled transmission could cause the loss of millions of 
lives and the potential collapse of health systems.6–9
Understanding the pattern of community transmission 
is essential to inform approaches to contain the spread 
of SARS- CoV-2. The role of transmission between house-
hold members is believed to have a significant role in the 
spread of the disease, where the secondary attack rate 
(SAR) is estimated to be 16.6%.10 This is reflected in the 
current UK government guideline where members of the 
household of a confirmed case are required to self- isolate 
for 10 days.11 Despite this, the limited availability of long- 
term prospective cohort studies means that further explo-
ration of how SARS- CoV-2 transmits within households, 
and a better understanding of how immune responses 
develop over time is urgently needed.10 12
In October 2020, the Liverpool City Region became 
the first area in England, UK, to be placed in the highest 
level of regional restriction after experiencing one of the 
highest rate of infection in the country.13 The region was 
also chosen as the site for the pilot asymptomatic mass 
testing due to its high infection rate during the second 
national lockdown.14 The transmission characteristic 
of the Liverpool City Region could be explored further 
through a community study of the virus transmission. 
These data would aid understanding of the transmis-
sion dynamics of SARS- CoV-2 that may be beneficial in 
informing public health interventions.
The Liverpool Household COVID-19 Cohort Study 
(COVID- LIV) is a prospective observational study of 
households in the Liverpool City Region. As a household- 
based study, COVID- LIV will capture paucisymptomatic 
and asymptomatic COVID-19 cases. This allows measure-
ment of the role of different disease manifestation of 
COVID-19 cases in the transmission of SARS- CoV-2 
between household members. In addition, the prospec-
tive nature of the study allows characterisation of the 
immune response to SARS- CoV-2 at different stages of the 
infection and determine the durability of the response.
STUDY AIMS
Among households in the Liverpool City Region, the 
primary aim is to understand household associated 
SARS- CoV-2 transmission. This aim will be achieved by:
1. Measurement of household COVID-19 incidence and 
SARs.
2. Identification of the determinants of transmission of 
SARS- CoV-2.
3. Estimation of the contribution of paucisymptom-
atic and asymptomatic infection to the spread of 
SARS- CoV-2.
Secondary aims are:
1. Measure family member contact patterns and the rela-
tionship to household structure.
2. Describe the clinical phenotype of mild COVID-19 cas-
es.
3. Undertake sequence of SARS- CoV-2.
4. Characterise the immune response in mild COVID-19 
cases.
5. Characterise the immune response of exposed house-
hold contacts with no subsequent detection of con-
firmed infection.
6. Investigate the prevalence of household faecal shed-
ding of SARS- CoV-2.
METHODS AND ANALYSIS
Design
COVID- LIV is a prospective observational cohort study of 
households in the Liverpool City Region, UK. Cohorts are 
followed up for an initial period of 12 weeks and then up 
to 3 years, observing the incidence of household trans-
mission of SARS- CoV-2 and characterising changes in 
the immune response over time. For 12 weeks, all house-
hold members are requested to perform weekly self- 
administered throat and nasal swabbing, along with the 
collection of blood and other clinical samples at different 
time points of the study. The study started in July 2020 
and is expected to continue until September 2023.
There are social science studies linked to this house-
hold study, including longitudinal surveys of all these 
households focusing on the impacts of the pandemic on 
the residents included in this research. In addition, there 
will be in- depth qualitative interviews at baseline and 3 
months with a purposive sample of these households, 
focusing on risk perception beliefs and actions.
Study population
Households are recruited from the large metropolitan 
Liverpool City Region in North West England, UK. The 
Liverpool City Region comprises six local authorities and 
has a population of over 1.5 million people. Almost 50% 
of its population are categorised as living in the 20% most 
deprived areas of England.15
Recruitment procedure
Households were recruited from the established Liver-
pool household survey undertaken by the National Insti-
tute for Health Research Collaboration for Leadership 
in Applied Health Research and Care (CLAHRC, now 
ARC).16 The established study framework contains over 
7000 households, representing a spectrum of demo-
graphic and socioeconomic characteristics. The initial 
selection process was undertaken by ARC team members 
with appropriate permission to access the original survey 
data. Individuals who indicated a willingness to be recon-
tacted for further research participation were identified 
and contacted by the COVID- LIV study team about their 
potential participation in this study.
To supplement the number of recruits, other methods 
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include text messages sent from local general practitioner 
(GP) surgeries to their patients containing information 
about the study and sharing study information through 
the University of Liverpool media, local media outlets 
and the social media of the researchers and stakeholder 
organisations. Interested households that contacted the 
study team are recruited if they fulfil the study criteria as 
follows:
Inclusion criteria
1. All people in the household willing to take part.
2. At least one adult within the household must speak En-
glish and willing to translate.
3. Have provided informed verbal and written consent or 
personal legal consent for those lacking capacity.
4. Ability and willingness to undertake self- swabbing.
5. Intention to be resident for at least 6 months within 
their current household, except for students, military 
personnel and other professions who may have to move 
away from home for purposes of study or employment
Exclusion criteria
1. Contraindication to throat and nasal swab or blood 
sampling.
2. One or more members of the household have had 
a proven COVID-19 test (positive PCR test for SARS 
CoV-2).
3. No members of the household can speak English.
A household comprises those individuals who reside at 
the household at the date of contact, even if they do not 
believe this is their primary residence and are intending 
to stay for at least 6 months beyond the date of enrolment 
and first sampling. Regularly attending persons such as 
carer and cleaner are classified as attendees and are asked 
to participate in the study, although their participation 
status does not affect the eligibility of the household. A 
participant aged 16 years or above is considered an adult.
Participant pathway
This section provides the pathway details of study partici-
pant from enrolment up to the end of the study (figure 1).
Consent procedure
The consent process consists of two phases: an intro-
ductory communication, followed by a visit to establish 
consent and sampling. At the first phase, potential house-
holds from the list of contacts from ARC will be contacted 
by phone or email wherever possible for ease and speed 
of communication and to minimise transmission risk. 
The same method of communication applies to partici-
pants that directly contacted the study team in response 
to advertisement through GP surgeries and other forms 
of media communication. During this phase, potential 
participants are given a brief explanation about the study, 
access to information on the study website is confirmed 
and any queries are answered.
Following initial contact and expression of interest by 
the household, a visit arrangement by research nurses is 
made. During the visit, where every household member 
is expected to be present, printed information sheets are 
provided along with further discussions on the purpose 
of the study and procedures required (see online supple-
mental appendix file 1). Written informed consent is 
expected to be provided for each member of the house-
hold. In addition to the parent or guardian consent form, 
children are provided with age- relevant information 
sheets; assent is obtained if the child is aged 8–15 years 
old and deemed capable of assessing the study documen-
tation provided.
Baseline visit
After written consent forms have been acquired from all 
household members, a baseline visit date is arranged. The 
visit is done on the day the consent forms are signed, or 
another date is arranged if necessary. During the baseline 
visit, the research nurses collect throat and nasal swab, 
blood samples (or finger prick sample if not suitable for 
venepuncture), nasal mucosal sample and saliva sample 
from all adult participants. Only a finger prick sample and 
saliva sample are collected from children. The research 
nurses also train the participants on how to perform 
throat and nasal swabbing themselves. Instruction on the 
procedure of self- swabbing is given to each household, 
along with the swab kits for the following weeks.
The first 12 weeks of participation
Participants are instructed to perform self- throat and 
nasal swab every week for a total of 12 weeks after enrol-
ment; samples are collected by a courier. A questionnaire 
is sent each week through email or phone call if no email 
address is provided, requesting information about the 
participant’s health condition and activities from the past 
7 days. Participants are also asked to report any COVID-19 
test done outside the study system, both during and 
after the initial 12 weeks of self- swabbing. Optional stool 
samples are collected from consenting participants at 
weeks 6–8 and 12–14 from enrolment.
Positive swab and result notification
If a positive SARS- CoV-2 swab result occurs during the 
first 12 weeks of self- throat and nasal swabbing, partici-
pants are informed of the result within 72 hours of sample 
receipt at the laboratory. Positive case details are passed 
to the National Health Service (NHS) test and trace 
according to Public Health England statutory require-
ment. On notification, participants are given information 
on self- isolation and are provided with other relevant 
guidelines from the UK government and the NHS. The 
participant’s GP is also informed, and additional clinical 
advice is available from the infectious diseases team at 
Liverpool University Hospitals NHS Foundation Trust or 
Alder Hey Children’s Hospital NHS Foundation Trust if 
deemed necessary by the study clinical team.
Following notification, a household visit is arranged 
to obtain additional samples of blood (or finger prick), 
throat and nasal swab, nasal mucosal swab and saliva from 
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is expected to be done within 3 days following result noti-
fication; repeat visits are arranged at 14 days and 12 weeks 
after result notification. If a participant has more than 
one positive PCR swab result during the course of the 
study, this will trigger restart of the additional sampling 
schedule if more than 6 weeks have elapsed from the first 
positive test in order to identify reinfection.
Follow-up visits
The first follow- up visit is performed at 12 weeks after 
enrolment for households with and without COVID-19 
cases. Samples of blood (or finger prick) are collected 
from households with no positive case, while samples 
of blood (or finger prick), throat and nasal swab, nasal 
mucosal swab and saliva are collected from households 
with at least one positive case. Repeat visits to house-
holds with a history of a positive throat and nasal swab, 
or seropositivity at baseline or at 12- week follow- up, will 
be conducted at 6 months, 1 year, 2 years and 3 years 
postenrolment.
Clinical sample and laboratory investigation
The following section provides more detail on the clinical 
samples that are obtained at different time points during 
the study (table 1).
Throat and nasal swab
A combined throat and nasal swab are taken for detection 
of SARS- CoV-2 at baseline by the participant under the 
guidance from the research nurses. Swabs are then taken 
by the participants at home and collected on a weekly basis 
for 12 weeks. This sample is collected using nylon flocked 
dry swabs placed into plastic tubes and transported to 
the laboratory to be tested within 72 hours. Participants 
are asked to perform self- swabbing on the night before 
or in the morning of collection day, where samples are 
then collected within 12–24 hours. Samples are placed 
inside a specimen bag and specimen cardboard box 
and stored at ambient temperature until collection and 
during transport. Swabs are processed for RNA extraction 
(Zymo Research) and qPCR (Primer Design Novacyt). 
Remaining Amies medium and extracted nucleic acid will 
be stored for future virology research.
Virus sequencing
Nucleic acid from positive throat and nasal swabs (and a 
small number of negative swabs as controls) will be trans-
ferred to the Centre for Genomic Research, University 
of Liverpool for SARS- CoV-2 whole- genome sequencing 
using the nanopore technology and the ARTIC network 
protocol.17 18
Blood sample
Up to 60 mL of whole blood are collected from each 
adult participant (or finger prick sample, if unsuitable for 
venepuncture). Children under the age of 16 years will 
have finger prick and blood spot collection rather than 
venepuncture and a smaller amount of blood collected.
The baseline and 12- week follow- up blood samples 
will be used to determine the prevalence of exposure 
to SARS- CoV-2 at a certain point of the epidemic. These 
data will be used to supplement virology data to maximise 
the identification of SARS- CoV-2 exposure.
Peripheral blood mononuclear cells (PBMCs) will be 
isolated from different time points of infection using 
Ficoll density centrifugation. Briefly, blood collected 
from sodium heparin tubes will be placed on a Ficoll 
cushion and centrifuged to retrieve PBMCs. Cells will 
then be washed and frozen down in 90% fetal bovine 
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PCR swab positive 
participants/household 










Throat and nasal 
swab
× ×   ×   × 
Blood samples ×     × × ×
Stool Sample     ×* ×     
Nasal mucosal 
sample
×‡     ×‡   ×‡
Saliva sample ×     ×   ×
*Optional – additional consent required.
†Samples taken at day 3 and day 14 after PCR swab positive test.
‡Adult participant only.
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serum and 10% dimethyl sulfoxide for downstream 
assays.
Antibody responses
The antibody response will be measured over time at base-
line, 12 weeks, 6 months, and 1, 2 and 3 years postinfection 
by ELISA, pseudovirus neutralisation and SARS- CoV-2 
neutralisation in a subset. The proportion of participants 
positive at each time point will be determined, and the 
magnitude of antibody titres will be measured. If positive 
cases are detected, neutralising antibody titres will be 
measured, and virus isolation will be attempted allowing 
testing of the serum neutralising capacity against the 
actual virus infecting the participant. Mucosal antibody 
and cytokine responses will be tested. These experiments 
will determine whether serum antibody measurements 
correlate with mucosal antibody and whether either is an 
adequate correlate of immunity. Parallel samples from 
household contacts (who are highly likely to be exposed) 
will also be collected and studied in order to determine 
what, if any, factors protect against the acquisition of 
infection or correlate with sterilising immunity.
T cell responses
Antigen- specific responses will be measured following ex 
vivo stimulation with SARS- CoV-2 peptide pools. PBMCs 
isolated at the various time points will be stimulated with 
various peptide pools and intracellular cytokine stain, and 
activation marker assays will be performed to characterise 
the SARS- CoV-2 T cell responses. Single- cell RNA- seq 
assays will also be done to explore the breadth of the T 
cell response to determine qualitative differences in the T 
cell repertoire. Where sample allows, T cell epitopes will 
be mapped using a synthetic peptide library and tested 
for cross- reactivity against common cold coronaviruses.
Innate response
Whole blood stored in RNA stabilisation solution (tempus 
tubes) will be subjected to RNA isolation and sequencing 
to characterise the innate immune response. These data 
will inform and refine the above experiments and have 
the potential to be related to the ISARIC 4C dataset 
(hospitalised severe cases) as a mild disease group.19
Genomic testing
Human leucocyte antigen typing will be undertaken 
along with characterisation of other important immune 
mediating characteristics, such as angiotensin receptor 2.
Stool sample
Stool samples are collected from adult participants who 
test positive from a PCR swab and from their consenting 
household contacts at approximately 3 and 14 days after 
confirmation of a positive PCR. Samples are transported 
to the University of Liverpool where they are frozen 
down for downstream assays, including for SARS- CoV-2 
sequencing. Additionally, optional stool samples are 
requested from all participants at two time points from 
their enrolment at approximately week 6–8 and week 
12–14.
Nasal mucosal and saliva sample
At the baseline visit, nasal mucosal and saliva samples 
are collected from adult participants and all participants, 
including children, respectively. The nasal mucosal 
sample is collected using synthetic absorptive matrix 
strips, and saliva sample is collected using ORACOL+ 
(Malvern Medical Developments), both are collected for 
antibody analyses. Additional samples are also collected 
from adult participants who subsequently tested positive 
from PCR swab and their household contacts.
Outcome measures
Primary endpoints
1. Incidence of paucisymptomatic and asymptomatic 
SARS- CoV-2 infections index cases, including the prev-
alence of infection or past infection at baseline serol-
ogy status.
2. Incidence of secondary household cases.
3. Risk factors for household transmission.
Secondary endpoints
1. Analysis of household contact patterns.
2. Description of clinical phenotypes of the index cases.
3. Genomic characterisation of SARS- CoV-2.
4. Characterisation of the immune response in index cas-
es and exposed household contacts.
5. Prevalence of SARS- CoV-2 household faecal shedding.
Data analysis
The results of the analyses will be reported according 
to the Strengthening the Reporting of Observational 
Studies in Epidemiology guidelines.20 This will include 
a descriptive analysis of households, paucisymptomatic 
and asymptomatic primary household index cases and 
secondary household cases.
Environmental, demographic and behavioural risk 
factors for secondary transmission among household 
contacts of symptomatic and laboratory- confirmed cases 
of COVID-19 will be investigated. Cases in households will 
be ordered by date of symptom onset. The first symptom-
atic COVID-19 case in the household will be classified as 
the probable household index case. Secondary COVID-19 
cases will be defined as any COVID-19 case with an onset 
of illness within 7 days following the onset of the index 
case.
The primary attack rate will be calculated as the number 
of households with a primary case divided by the total 
number of households in the study. The household SAR 
will be calculated from the number of households with at 
least one secondary COVID-19 case divided by the total 
number of households at risk. The individual household 
members attack rate will be calculated from the number 
of household members with secondary COVID-19 illness 
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Index cases will be described in relation to demo-
graphics, employment and contact history. A risk factor 
analysis will be undertaken to investigate variables associ-
ated with secondary attack cases within households. Risk 
factors will include data on contacts, viral load measure-
ments, household characteristics and other variables 
that emerge in external reports or literature that may be 
linked with transmission.
Data and statistical analysis of serology and other immu-
nological parameters will be done using GraphPad Prism, 
FlowJo V.10, R and other bioinformatics software.
Sample size
The study should be regarded as exploratory. The initial 
constraints on sample size are primarily access to testing 
on a weekly basis. Referring to the current data on the 
SAR of 10.5%–45% of contacts with a HR of 1.5 or 2.0, 
using a single sample Cox proportional hazard model 
with 80% power and 10% study withdrawal, we propose an 
initial sample size of 300 households, which will contain 
approximately 1000 individuals.21–23
Patient and public involvement (PPI)
The protocol has been reviewed by the PPI committee 
of the Institute of Infection, Veterinary, & Ecological 
Sciences, University of Liverpool. The study design, partic-
ipant acceptability and perceptions have been reviewed 
and discussed. The necessary speed to get this work up 
and underway has prevented a more standard input from 
the PPI group. Test results will be reported to participants 
in plain language.
ETHICS AND DISSEMINATION
The study has received approval from the NHS Research 
Ethics Committee; REC Reference: 20/HRA/2297, IRAS 
Number: 283 464. Protocol amendments have been and 
will be reported to the Research Ethics Committee, as 
will any serious adverse events. The study participants are 
informed that all data collected are for research purposes 
only and that they have the right to withdraw from the 
study at any time.
Project governance
The study is coordinated by the Liverpool Clinical Trials 
Centre, University of Liverpool. A study steering group 
has been established to enable effective achievement 
of the project objectives. The steering group includes 
representatives from academia, public health and lay 
membership.
Dissemination of research findings
The findings will be presented at professional and scien-
tific conferences. The results will also be published in 
peer- review publications and, if appropriate, published 
first as preprints to enable a timely public health response 
to COVID-19. Interim and final reports will be submitted 
to the funders and the steering group. We also work with 
our institute PPI panel to identify and produce materials 
to disseminate to the general public, including study 
participants.
DISCUSSION
COVID- LIV will demonstrate the role of household trans-
mission of SARS- CoV-2 in a cohort of households in the 
Liverpool City Region, UK. By observing households 
with no apparent previous infection of COVID-19, it is 
hoped that the incidence, determinants of transmission 
and contribution of paucisymptomatic and asymptom-
atic cases can be described, filling a knowledge gap in 
how the disease transmits within the population in the 
Liverpool City Region. Characterising immune responses 
in a cohort of mild infections will provide a better 
understanding of how natural infection alters immune 
parameters over time, allowing a better understanding 
of immunity against COVID-19 infection that may help 
inform vaccine development and delivery.
Strengths
COVID- LIV aimed to recruit a cohort of households 
across a representative range of socioeconomic status in 
the Liverpool City Region. The household cohort allows 
for identification of paucisymptomatic and asymptom-
atic COVID-19 cases, which will provide a better repre-
sentation of the impact of COVID-19 in the community 
and extent of transmission through the sampling of high 
probability exposed household members. The prospec-
tive nature of the study allows the determination of a true 
incidence rate and risk factors for SARS- CoV-2 transmis-
sion with less recall bias. The longitudinal study design 
enables the analysis of the immunological response and 
faecal shedding of SARS- CoV-2 during different stages 
of the disease. It also allows observation of the natural 
progression of mild cases from a preinfection stage sample 
collection to allow the interrogation of T cell repertoires 
and their association with acute infection.
Limitations
The cohort households may be biased by those that 
are most engaged with COVID-19 and disease control, 
leading to a low level of secondary infections as partic-
ipating individuals are more likely to take precautions 
against transmission. Low level of detectable infections 
may also be observed due to the study observation across 
different seasonality time points. Reliance on repeated 
self- sampling may lead to diagnostic inconsistencies, 
although instructions were given, and techniques were 
carefully assessed by the research nurses during the initial 
baseline visit. Exclusion of non- English- speaking families 
may exclude potential high- risk households resulting in 
under detection of incidence rate and more severe cases.
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